NCT00870025 (APPE) is a Phase 4 clinical trial of human chorionic gonadotropin in Ovarian Response, sponsored by IVI Madrid.

Who is sponsoring NCT00870025?

NCT00870025 is sponsored by IVI Madrid.

What drugs are being tested in NCT00870025?

Interventions in NCT00870025: human chorionic gonadotropin, placebo.

What condition does NCT00870025 study?

NCT00870025 studies Ovarian Response.

Is NCT00870025 still recruiting?

NCT00870025 is currently completed. Last updated 21 April 2015.

Last reviewed 2015-04-21 · How we verify

NCT00870025: APPE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

hCG Priming Prior to COH in Poor Responder IVF Patients

Completed Phase 4 Last updated 21 April 2015

What this trial tests

Phase 4 trial testing human chorionic gonadotropin in Ovarian Response in 60 participants. Completed in 1 September 2010.

Timeline

1 October 2008

Primary endpoint
1 September 2010

1 September 2010

Quick facts

Lead sponsor	IVI Madrid
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	60
Start date	1 October 2008
Primary completion	1 September 2010
Estimated completion	1 September 2010
Sites	1 location across Spain

Drugs / interventions tested

human chorionic gonadotropin — full drug profile →
placebo

Conditions studied

Ovarian Response — all drugs for Ovarian Response →

Sponsor

IVI Madrid — full company profile →

Who can join

Adults 18 to 41, female only, with Ovarian Response. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

pregnancy rate
Time frame: 2 weeks after intervention

Sponsor's own description

There is a decline in androgen concentration with ovarian aging. Also, ovarian response to COH in IVF cycles diminishes with ovarian aging. Recent evidence suggest that testosterone or DHEA may improve ovarian response in poor prognosis patients by increasing intraovarian androgen concentration. A physiological way to induce androgen synthesis within the ovary is to stimulate theca cells androgen production by hCG stimulation. By doing this in the previous cycle we might expect a better response to COH.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of human chorionic gonadotropin

Trials testing the same drug.

NCT06754332 — The Study of Human Chorionic Gonadotropin (HCG) Activating the Dormant Follicles . · Phase 1 · not yet recruiting
NCT05586802 — Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome · Phase 3 · recruiting
NCT05076981 — Progesterone Levels During Ovulation and Luteal Phase · completed
NCT03418896 — Extragonadal Effects of hCG on Calcium Homeostasis · Phase 1 · completed
NCT05393011 — Relationship Between Some Vitamins and Antioxidants With in Vitro Fertilization Outcomes · completed

Other IVI Madrid trials

Trials by the same sponsor.

NCT06244745 — Effects of Letrozole During the Luteal Phase After Controlled Ovarian Stimulation in Oocyte Donors. · Phase 3 · recruiting
NCT05606679 — Maternal KIR and Fetal HLA Influence Reproductive Success in ART-oocyte Donor. · unknown
NCT05508217 — Impact of Telomere Biology and Sperm DNA Fragmentation on Embryonic Development · unknown
NCT02718105 — Maternal and Fetal Compatibility in Assisted Reproductive Technology (ART)-Oocyte Donor Influences Live Birth Rate · completed
NCT04778358 — Higher Dose of Rekovelle in Oocyte Donors · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00870025 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by IVI Madrid
Last refreshed: 21 April 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00870025.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing